Bioactive Small Molecules
Cayman Chemical ANTIBODY Aspartame 50g
A synthetic non-caloric sweetener; metabolized to phenylalanine, aspartic acid, and methanol in the gut; increases plasma ALT and AST activity, induces hepatocyte degeneration and leukocyte infiltration in the liver, and reduces hepatic levels of GSH, GSSG, and γ-GC in mice at 80 mg/kg per day for 90 days
Cayman Chemical 4-palmItamIdo TEMPO 5mg
A lipid-soluble spin label; incorporates into vesicles and cell membranes; has been used to study the entrapment of molecules within phosphatidylcholine vesicles
Cayman Chemical ANTIBODY LaquInImod 500mg
An orally bioavailable immunomodulator; induces expression of genes related to antigen presentation and inflammatory pathways in human PBMCs in vitro (0.1 μM); decreases the severity of symptoms by 91.4% and the number of relapses in mouse models of aEAE and crEAE, respectively (5 mg/kg per day); decreases T cell and macrophage density and demyelination in the spinal cord of EAE mice compared to non-treated controls (5 mg/kg per day); decreases inflammatory lesions and demyelination in the sciatic nerve in a rat EAN model (12.5 and 25 mg/kg per day); activates gene expression in the AhR pathway in splenocytes from EAE mice with no effect in AhR knockout mice (25 mg/kg per day)
Apexbio Technology LLC Punicalagin 65995-63-3 20mg
Punicalagin (CAS 65995-63-3) is a small-molecule inhibitor targeting NF- B and MAPK signaling pathways It is designed to modulate these key inflammatory signaling cascades thereby regulating immune and inflammatory responses Punicalagin exerts its biological activity primarily through inhibition of inflammatory cytokine production and immune response signaling In cellular and animal-based studies punicalagin demonstrates inhibitory activity with IC50 values ranging from approximately 10 to 50 M depending on cell type and assay conditions Based on these pharmacological properties punicalagin holds research potential in immunology virology autoimmune disease models and inflammation-related pathogenesis
Apexbio Technology LLC JNJ-10198409 627518-40-5 5mg
JNJ-10198409 (CAS 627518-40-5) is a small molecule inhibitor targeting the tyrosine kinase activity of the platelet-derived growth factor (PDGF-BB) receptor This compound acts as a competitive antagonist at the ATP-binding site of the PDGF-BB receptor thereby inhibiting downstream signaling involved in cell proliferation migration and angiogenesis In human coronary artery smooth muscle cells JNJ-10198409 demonstrated an IC50 of 4 2 nM for inhibition of PDGF-BB receptor kinase activity It has been utilized in research to study the modulation of tumor growth angiogenesis and PDGF-driven pathologies
Cayman Chemical ANTIBODY HesperadIn 10mg
A multi-kinase inhibitor; inhibits human Aurora kinase B (IC50 = 250 nM) and the T. brucei homolog Aurora kinase-1 (IC50 = 40 nM); inhibits AMPK, LCK, MKK1, MAPKAP-K1, CHK1, and PHK in a panel of 25 kinases at 1 µM; inhibits MEKK2 in ATPase and transphosphorylation assays (IC50s = 60 and 34 nM, respectively); induces polyploidy and defects in cytokinesis and spindle assembly as well as inhibits proliferation of HeLa cells and overrides paclitaxel- and monastrol-induced mitotic arrest from 50-100 nM; induces toxicity in HepG2 cells (TC50 = 50 = 0.22-2.21 µM); inhibits the growth of T. brucei, L. major promastigotes and amasigotes, and P. falciparum (EC50s = 0.01-2.37 µM)
Cayman Chemical ANTIBODY FIpronIl 50mg
An insecticide; a selective antagonist of insect GABA receptors (IC50s = 28 and 1,660 nM for cockroach and rat receptors, respectively); inhibits desensitizing and non-desensitizing glutamate-induced chloride currents in cockroach neurons (IC50s = 800 and 10 nM, respectively); induces CYP1A1/2, CYP2B1/2, and CYP3A1/2 activity in isolated rat liver microsomes
Apexbio Technology LLC ZM 241385 139180-30-6 5mg
ZM 241385 is a selective high-affinity antagonist targeting the adenosine A2A receptor (A2AR) It is designed to inhibit A2AR-mediated signaling thereby modulating receptor-specific downstream pathways ZM 241385 exerts its biological activity primarily through competitive inhibition of A2AR It demonstrates antagonistic activity with a Ki value of approximately 1 4 nM Based on these pharmacological properties ZM 241385 holds research potential in studies of neurodegenerative disorders cardiovascular conditions and A2AR-mediated neuronal signaling pathways
Apexbio Technology LLC QX 314 bromide 24003-58-5 100mg
QX 314 bromide (CAS 24003-58-5) is a membrane-impermeant quaternary derivative of lidocaine that functions as a local anesthetic It blocks voltage-gated sodium channels inhibiting Na -dependent action potentials and non-inactivating sodium conductance as demonstrated in hippocampal CA1 pyramidal neurons In vitro QX 314 bromide modulates TRPV1 channels higher concentrations (10 60 mM) activate TRPV1 while submicromolar concentrations inhibit capsaicin-induced TRPV1 currents with an IC50 of 8 0 M When administered with flagellin it suppresses sodium currents in large-diameter human dorsal root ganglion neurons and inhibits mechanical allodynia in neuropathic pain models QX 314 bromide is utilized in studies on neuronal excitability pain mechanisms and long-lasting local anesthesia
Cayman Chemical ANTIBODY MK-0974 10mg
A CGRP receptor antagonist (Ki = 0.77 μM); binds selectively to the human CGRP receptor complex over the adrenomedullin receptor complexes in HEK293 cells (Kis = >100 and 29 μM for CRLR with RAMP2 and 3, respectively); inhibits CGRP-induced cAMP accumulation in HEK293 cells expressing the CGRP receptor complex (IC50 = 2.2 nM); reduces CGRP-induced vasodilation in isolated human meningeal arteries; inhibits vasodilation induced by topical application of capsaicin in rhesus monkeys (EC50 = 127 nM)
Apexbio Technology LLC NSC 663284 383907-43-5 10mg
NSC 663284 (CAS 383907-43-5) is a small molecule belonging to the quinolinedione class characterized as an inhibitor of Cdc25 phosphatases By targeting Cdc25 enzymes it interferes with the dephosphorylation of cyclin-dependent kinases a process essential for cell cycle progression NSC 663284 is utilized in biomedical research to study cell cycle regulation mechanisms and has potential utility in exploring therapeutic strategies aimed at modulating mitotic control in proliferative diseases
Selleck Chemical LLC Enarodustat S9656-5MG
Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0 22 M for PHD2 and EC50 of 5 7 M for EPO release from Hep3B cells Enarodustat has the potential for the treatment of renal anemia
Selleck Chemical LLC Amcenestrant S9609-25MG
Amcenestrant (SAR439859 compound 43d) is an orally available and nonsteroidal selective estrogen receptor degrader (SERD) with potential antineoplastic activity SAR439859 is a potent estrogen receptor (ER) antagonist with EC50 of 0 2 nM for ER degradation
Cayman Chemical Naloxon benzoylhydrazon 5mg
A μ-, κ1-, and δ-opioid receptor antagonist (pA2s = 8.82, 7.45, and 7.76, respectively, for the mouse receptors); a κ3-opioid receptor agonist (IC50 = 0.7 nM for the guinea pig receptor); inhibits increases in the latency to tail withdraw induced by DAMGO in a hotplate assay in mice at 1 UG/animal, i.c.v.; increases food intake in rats at 0.1, 1, and 20 UG/animal, i.c.v.
Medchemexpress LLC Elimusertib hydrochloride | 99.9% | 411.89 | 100 MG
Elimusertib hydrochloride (BAY 1895344) is a potent, orally active, and selective ATR inhibitor with an IC50 of 7 nM. It demonstrates anti-tumor activity and can be used for research on solid tumors and lymphomas.
- Potent, orally active, and selective ATR inhibitor
- Demonstrates anti-tumor activity
- Applicable for research on solid tumors and lymphomas
- Inhibits proliferation of human tumor cell lines
- Suppresses hydroxyurea-induced H2AX phosphorylation
- Shows good selectivity against related kinases
- Potent antiproliferative activity against various cancer cell lines in vitro
- Potent anti-tumor efficacy in monotherapy in xenograft models
- Causes complete tumor remission in mantle cell lymphoma models
- Synergistic antitumor activity with Carboplatin in relevant models
- Exhibits moderate oral bioavailability